Prevalence of eosinophilia in hospitalized patients with asthma exacerbation.

Respir Med

Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Published: September 2015

Background: Recent studies have identified the "eosinophilic phenotype" of asthma that is characterized by persistent eosinophilic inflammation and frequent exacerbations. However, the prevalence of eosinophilia in patients hospitalized for asthma exacerbation is not known.

Methods: We performed a pilot study in two sites participating in a multicenter chart review project of children and adults hospitalized for asthma exacerbation during 2012-2013. The pilot study investigated the prevalence of blood eosinophilia in this patient population. Eosinophilia was defined as a count of ≥300 cells/microliter at some time during the hospitalization.

Results: Among 80 patients hospitalized for asthma exacerbation, 47 (59%) underwent CBC with differential and had data on blood eosinophil count. These 47 comprised the analytic cohort. The median patient age was 32 years (IQR, 24-44 years), and 51% were female. Overall, 40% (95% CI, 26%-56%) of patients had eosinophilia. Although statistical power was limited, there were no statistically significant differences in patient characteristics or hospital course between patients with eosinophilia and those without (all P > 0.05).

Conclusion: Our pilot study showed that 40% of patients hospitalized for asthma exacerbation had eosinophilia. The clinical meaning of this biomarker in the emergency department/inpatient setting requires further study in much larger samples with long-term follow-up; such studies appear feasible.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2015.07.011DOI Listing

Publication Analysis

Top Keywords

asthma exacerbation
20
hospitalized asthma
16
patients hospitalized
12
pilot study
12
prevalence eosinophilia
8
patients eosinophilia
8
patients
6
asthma
6
eosinophilia
6
hospitalized
5

Similar Publications

Allergic asthma is a significant international concern in respiratory health, which can be exacerbated by the increasing levels of non-allergenic pollutants. This rise in airborne pollutants is a primary driver behind the growing prevalence of asthma, posing a health emergency. Additionally, climatic risk factors can contribute to the onset and progression of asthma.

View Article and Find Full Text PDF

Introduction: The burden of severe asthma on patients, especially on those with concomitant chronic rhinosinusitis with nasal polyps (CRSwNP), is substantial. Treatment intensification with oral corticosteroids is a common strategy for managing severe asthma exacerbations; however, prolonged exposure to systemic corticosteroids is associated with multisystem toxicity. This study aimed to quantify the association between oral corticosteroid use and annual asthma-related costs in patients with severe asthma with or without CRSwNP.

View Article and Find Full Text PDF

Background: Chronic respiratory diseases (CRDs) have been shown to be associated with frailty, but these findings have not yet reached a consensus. The aim of this study was to investigate the association between CRDs and frailty in the elderly using a nationally representative data from China.

Methods: Data from the China Health and Retirement Longitudinal Study (CHARLS) were analysed, including 3309 frailty-free participants followed for three waves from 2011.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to analyze the cost-effectiveness of budesonide/formoterol compared to other asthma treatments at Mexico's National Institute for Respiratory Diseases.
  • Budesonide/formoterol had a lower average cost per patient ($733.36 USD) compared to fluticasone/vilanterol ($767.24 USD), and it showed a significant reduction in exacerbations with an incremental cost-effectiveness ratio (ICER) of $613.31 USD for better management.
  • Overall, budesonide/formoterol was found to be a very cost-effective treatment option, suggesting it could reduce healthcare costs associated with emergency visits and hospitalizations despite fewer exacerbations per patient.
View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is an age-related neurodegenerative disorder affecting nearly 50 million individuals worldwide. Besides aging, various comorbidities can increase the risk of AD, such as asthma. However, the molecular mechanism(s) underlying this asthma-associated AD exacerbation is unknown.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!